Literature DB >> 9648990

Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease.

T Griga1, A Tromm, J Spranger, B May.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic, vascular permeability-enhancing, and calcium-dependent enzyme-modulating cytokine with overexpression in various pathologic disorders, including granulomatous inflammation, tissue repair, delayed hypersensitivity reactions, rheumatoid arthritis, and tissue ischemia. The present study investigates the role of VEGF in chronic inflammatory bowel disease.
METHODS: Thirty-one patients with Crohn's disease, 15 patients with ulcerative colitis, and 9 healthy volunteers were studied. VEGF serum levels were measured with a solid-phase enzyme-linked immunosorbent assay.
RESULTS: Significantly increased VEGF serum levels were observed in both active Crohn's disease and active ulcerative colitis when compared with healthy controls. Patients with active Crohn's disease and active ulcerative colitis showed significantly higher VEGF serum levels than patients with quiescent disease. No difference was observed between inactive disease and healthy controls. In addition, strongly increased VEGF serum levels were found in patients with Crohn's disease with fistulas in the absence of clinical, endoscopic, histologic, and laboratory findings of disease activity.
CONCLUSIONS: Significantly increased VEGF serum levels were observed in patients with active Crohn's disease and ulcerative colitis, which suggests that VEGF has an important role in chronic inflammatory bowel disease. Its possible association with fistulas has yet to be determined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648990     DOI: 10.1080/00365529850172070

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  21 in total

1.  Structural adaptations in the murine colon microcirculation associated with hapten-induced inflammation.

Authors:  Dino J Ravnic; Moritz A Konerding; Akira Tsuda; Harold T Huss; Tanja Wolloscheck; Juan P Pratt; Steven J Mentzer
Journal:  Gut       Date:  2006-11-17       Impact factor: 23.059

2.  Leptin and vascular endothelial growth factor regulate angiogenesis in tooth germs.

Authors:  Shinji Ide; Reiko Tokuyama; Purevsuren Davaadorj; Masashi Shimozuma; Shuku Kumasaka; Seiko Tatehara; Kazuhito Satomura
Journal:  Histochem Cell Biol       Date:  2011-02-22       Impact factor: 4.304

3.  Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes.

Authors:  T Griga; S Werner; M Köller; A Tromm; B May
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

Review 4.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease.

Authors:  F Magro; F Araujo; P Pereira; E Meireles; M Diniz-Ribeiro; F Tavarela Velosom
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

6.  3,5-Disubstituted Isoxazole Derivatives: Potential Inhibitors of Inflammation and Cancer.

Authors:  Kodagahalli Sathya Rakesh; Swamy Jagadish; Kyathegowdanadoddi Srinivas Balaji; Farhan Zameer; Toreshettahally Ramesh Swaroop; Chakrabhavi Dhanajaya Mohan; Shankar Jayarama; Kanchugarakoppal Subbegowda Rangappa
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

7.  Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.

Authors:  Ana Teresa Carvalho; Heitor Souza; Antonio Jose Carneiro; Morgana Castelo-Branco; Kalil Madi; Alberto Schanaider; Flavia Silv; Fernando Antonio Pereira Junior; Marcia G Pereira; Claudio Tortori; Ilana Dines; Jane Carvalho; Eduardo Rocha; Celeste Elia
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

8.  Thalidomide for treatment of severe intestinal bleeding.

Authors:  J Bauditz; G Schachschal; S Wedel; H Lochs
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

9.  Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis.

Authors:  M Sekiya; A Ohwada; K Miura; S Takahashi; Y Fukuchi
Journal:  Lung       Date:  2003       Impact factor: 2.584

10.  Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction.

Authors:  Michael Fricker; Bridie J Goggins; Sean Mateer; Bernadette Jones; Richard Y Kim; Shaan L Gellatly; Andrew G Jarnicki; Nicholas Powell; Brian G Oliver; Graham Radford-Smith; Nicholas J Talley; Marjorie M Walker; Simon Keely; Philip M Hansbro
Journal:  JCI Insight       Date:  2018-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.